DOCSLIB.ORG

Varicella Vaccine Update

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Varicella Vaccine Update AMERICAN ACADEMY OF PEDIATRICS Committee on Infectious Diseases Varicella Vaccine Update ABSTRACT. Recommendations for routine varicella vaccine coverage are more than 90% for children 19 vaccination were published by the American Academy of to 35 months of age and more than 95% at school Pediatrics in May 1995, but many eligible children re- entry.6 Varicella deaths and severe morbidity, as well main unimmunized. This update provides additional in- as the societal disruption of children missing 5 to 7 formation on the varicella disease burden before the days of school or child care, have prompted states to availability of varicella vaccine, potential barriers to im- consider requirements for varicella immunization for munization, efforts to increase the level of coverage, new safety data, and new recommendations for use of the school and child care center entry. Several states and varicella vaccine after exposure and in children with the District of Columbia already have such require- human immunodeficiency virus infections. Pediatricians ments, and a number of other states have begun the are strongly encouraged to support public health officials implementation process. Children 12 months of age in the development and implementation of varicella im- or older without documentation of varicella immu- munization requirements for child care and school entry. nization or infection who do not have a contraindi- cation should receive a dose of varicella vaccine im- ABBREVIATIONS. AAP, American Academy of Pediatrics; ACIP, mediately. In addition, special emphasis should be Advisory Committee on Immunization Practices; CDC, Centers placed on immunization of susceptible older chil- for Disease Control and Prevention; CI, confidence interval; VZV, dren and adults, because the likelihood of severe varicella-zoster virus; VZIG, varicella-zoster immune globulin. infection increases with increasing age. aricella vaccine (Varivax, Merck and Com- POTENTIAL BARRIERS TO IMMUNIZATION WITH pany, Inc, West Point, PA) was licensed on VARICELLA VACCINE VMarch 17, 1995, by the US Food and Drug Potential barriers to achieving high rates of vari- Administration for use in healthy persons 12 months cella immunization among children include the fol- of age or older who have not had varicella. Recom- lowing: 1) the misconception that varicella is uni- mendations for vaccine use were published by the formly a mild disease; 2) concerns about vaccine American Academy of Pediatrics (AAP) in May 1995 effectiveness and safety; 3) concerns about waning and by the Advisory Committee on Immunization immunity; 4) concern that universal immunization of Practices (ACIP) in July 1996.1,2 Updated recommen- young children will shift the disease burden to older dations of the ACIP were published in May 1999.3 age groups among whom the disease is more severe; Despite the recommendations, many eligible chil- 5) the stringent storage and handling requirements dren remain unimmunized. Annualized estimates of the vaccine; 6) vaccine availability; 7) inadequate from July 1997 to June 1998 revealed that national insurance coverage; and 8) lack of requirements for varicella vaccine coverage of children 19 to 35 varicella vaccine for licensed child care and school months of age was 34% with wide variations in state entry.7 In addition, there is an inherent lag time and urban areas, ranging from 6% to 52% (Centers between issuance of recommendations and full in- for Disease Control and Prevention [CDC] unpub- corporation of the recommendations into immuniza- lished data, 1999). tion programs. Although some of these issues are no As a result of underutilization of varicella vaccine, longer barriers to immunization with varicella vac- hospitalizations, serious complications, and deaths cine, others remain. attributable to varicella infection continue to occur in 4,5 the United States. To increase vaccine coverage and VARICELLA DISEASE BURDEN reduce the current morbidity and mortality attribut- Varicella is a common, highly infectious disease able to varicella, the ACIP recently recommended that, in the absence of immunization, infects almost that a physician’s diagnosis of varicella, a reliable every person. Before the availability of the varicella history of the disease, serologic evidence of immu- vaccine, approximately 4 million cases occurred an- nity, or receipt of varicella vaccine be required for 3 nually in the United States, resulting in 10 000 hos- enrollment in child care centers and schools. In ad- pitalizations and 100 deaths.5 In the United States, dition, Healthy People 2010 objectives for varicella more than 90% of infections, two thirds of varicella- related hospitalizations, and almost half of varicella- related deaths occur in children.5 In children, vari- The recommendations in this statement do not indicate an exclusive course cella is one of the most important risk factors for of treatment or serve as a standard of medical care. Variations, taking into 8,9 account individual circumstances, may be appropriate. severe, invasive, group A streptococcal disease. Al- PEDIATRICS (ISSN 0031 4005). Copyright © 2000 by the American Acad- though the incidence of disease among adults is low, emy of Pediatrics. the risk of complications and death attributable to 136 PEDIATRICS Vol. 105Downloaded No. 1 January from www.aappublications.org/news 2000 by guest on September 27, 2021 varicella is 10- to 20-fold higher than that for chil- performed to determine the need, if any, for addi- dren. Despite the lower risks of severe morbidity and tional doses of varicella vaccine. mortality among children, the burden of disease is greatest among children since more than 90% of EFFECT OF VARICELLA VACCINE ON cases occur in this age group. Although the incidence EPIDEMIOLOGY OF VARICELLA of disease had been highest among children 5 to 9 There has been concern that use of varicella vac- years of age,10 in the 1990s, the highest incidence is in cine in young children will create a cohort of adults children 1 to 4 years of age.11,12 at risk for serious varicella disease. Currently, fewer than 2% of adults older than 30 years in the United EFFECTIVENESS OF VARICELLA VACCINE States are susceptible to varicella. As the use of vari- Varicella vaccine has been demonstrated to be cella vaccine increases, the circulation of wild-type very effective. Prelicensure, controlled, clinical trials VZV will decrease and the likelihood that children demonstrated varicella vaccine to be 70% to 90% unexposed to natural infection and unimmunized effective for preventing varicella and more than 95% will enter adolescence and adulthood without immu- effective for preventing severe varicella.13,14 A postli- nity will increase. Mathematical models predict that censure study of 148 children performed during an if varicella vaccine coverage in children is more than outbreak of varicella in a child care center in DeKalb 90%, a greater proportion of cases will occur at older County, GA, found that varicella vaccine was 86% ages, but the varicella disease burden will decrease (95% confidence interval [CI], 73%–92%) effective for for children and adults21 (Table 1). However, if im- preventing varicella and 100% (95% CI, 96%–100%) munization rates for young children with varicella effective for preventing moderate to severe disease. vaccine remain relatively low, the number of chil- Varicella was less severe and resulted in fewer days dren who become susceptible adults will increase as of absence from the day care center among immu- will the opportunities for these susceptible adults to nized compared with unimmunized cases.15 Two contract varicella from unimmunized children. more recent studies found that varicella vaccine was Therefore, physicians who withhold varicella immu- 86% (95%CI, 67%–94%) and 84% effective (95% CI, nization from young children because of fear of cre- 60%–94%), respectively, for preventing varicella and ating a cohort of adults at risk for serious varicella 100% effective for preventing severe varicella.16,17 disease may be creating a self-fulfilling prophecy.22 “Breakthrough” disease following exposure to wild- type varicella-zoster virus (VZV) occurs in about 1% COST-BENEFIT OF VARICELLA VACCINE to 4% of vaccinees per year, and the rate does not In recent years, several cost-benefit analyses of seem to increase with length of time after immuni- varicella vaccine programs have been performed23–25 zation.18 “Breakthrough” disease is usually of short (Table 2). In 1994, Lieu and coworkers23 reported the duration and mild with fewer than 50 lesions and results of a cost-benefit analysis of a program that low-grade or no fever. provided varicella vaccine to all children in the United States younger than 6 years. That same year, DURATION OF IMMUNITY Huse and coworkers24 reported the results of a cost- Although there has been concern about waning benefit analysis of a program that provided routine immunity, follow-up evaluations of children immu- varicella immunization to a hypothetical cohort of nized during prelicensure clinical trials in the United 100 000 children in the United States aged 15 months. States revealed protection for at least 11 years, and In 1996, Beutels and coworkers25 reported the results studies in Japan indicated protection for at least 20 of a cost-benefit analysis of a program that provided years.19,20 However, these studies were during a pe- routine varicella immunization to all children in Ger- riod when a substantial amount of wild-type VZV many between 12 and
Load more

Recommended publications
  • Healthcare Personnel Vaccination Recommendations1 Vaccine ­ Recommendations in Brief ­
    Healthcare Personnel Vaccination Recommendations1 Vaccine Recommendations in brief Hepatitis B Give 3-dose series (dose #1 now, #2 in 1 month, #3 approximately 5 months after #2). Give IM. Obtain anti-HBs serologic testing 1–2 months after dose #3. Influenza Give 1 dose of influenza vaccine annually. Give inactivated injectable influenza vaccine intramuscularly or live attenuated influenza vaccine (LAIV) intranasally. MMR For healthcare personnel (HCP) born in 1957 or later without serologic evidence of immunity or prior vaccination, give 2 doses of MMR, 4 weeks apart. For HCP born prior to 1957, see below. Give SC. Varicella For HCP who have no serologic proof of immunity, prior vaccination, or history of varicella disease, (chickenpox) give 2 doses of varicella vaccine, 4 weeks apart. Give SC. Tetanus, diphtheria, Give a one-time dose of Tdap as soon as feasible to all HCP who have not received Tdap previously. pertussis Give Td boosters every 10 years thereafter. Give IM. Meningococcal Give 1 dose to microbiologists who are routinely exposed to isolates of N. meningitidis. Give IM or SC. Hepatitis A, typhoid, and polio vaccines are not routinely recommended for HCP who may have on-the-job exposure to fecal material. Hepatitis B Healthcare personnel (HCP) who perform tasks that may involve exposure to of live rubella vaccine). HCP with 2 documented doses of MMR are not blood or body fluids should receive a 3-dose series of hepatitis B vaccine at recommended to be serologically tested for immunity; but if they are tested 0-, 1-, and 6-month intervals. Test for hepatitis B surface antibody (anti-HBs) and results are negative or equivocal for measles, mumps, and/or rubella, to document immunity 1–2 months after dose #3.
    [Show full text]
  • Mmrv Vaccine
    VACCINE INFORMATION STATEMENT (Measles, Mumps, Many Vaccine Information Statements are available in Spanish and other languages. MMRV Vaccine Rubella and See www.immunize.org/vis Varicella) Hojas de información sobre vacunas están disponibles en español y en muchos otros What You Need to Know idiomas. Visite www.immunize.org/vis These are recommended ages. But children can get the Measles, Mumps, Rubella and second dose up through 12 years as long as it is at least 1 Varicella 3 months after the first dose. Measles, Mumps, Rubella, and Varicella (chickenpox) can be serious diseases: Children may also get these vaccines as 2 separate shots: MMR (measles, mumps and rubella) and Measles varicella vaccines. • Causes rash, cough, runny nose, eye irritation, fever. • Can lead to ear infection, pneumonia, seizures, brain 1 Shot (MMRV) or 2 Shots (MMR & Varicella)? damage, and death. • Both options give the same protection. Mumps • One less shot with MMRV. • Causes fever, headache, swollen glands. • Children who got the first dose as MMRV have • Can lead to deafness, meningitis (infection of the brain had more fevers and fever-related seizures (about and spinal cord covering), infection of the pancreas, 1 in 1,250) than children who got the first dose as painful swelling of the testicles or ovaries, and, rarely, separate shots of MMR and varicella vaccines on death. the same day (about 1 in 2,500). Rubella (German Measles) Your doctor can give you more information, • Causes rash and mild fever; and can cause arthritis, including the Vaccine Information Statements for (mostly in women). MMR and Varicella vaccines.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • The Safety of Influenza Vaccines in Children
    Vaccine 33 (2015) F1–F67 Contents lists available at ScienceDirect Vaccine j ournal homepage: www.elsevier.com/locate/vaccine Review The safety of influenza vaccines in children: An Institute for Vaccine ଝ,ଝଝ Safety white paper a,b,∗ b,c d a Neal A. Halsey , Kawsar R. Talaat , Adena Greenbaum , Eric Mensah , a,b a,b a,b Matthew Z. Dudley , Tina Proveaux , Daniel A. Salmon a Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States b Institute for Vaccine Safety, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, United States c Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States d Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, United States a r t i c l e i n f o a b s t r a c t Keywords: Most influenza vaccines are generally safe, but influenza vaccines can cause rare serious adverse events. Influenza Some adverse events, such as fever and febrile seizures, are more common in children than adults. There Influenza vaccine can be differences in the safety of vaccines in different populations due to underlying differences in Vaccine safety genetic predisposition to the adverse event. Live attenuated vaccines have not been studied adequately Local reactions following IIV in children under 2 years of age to determine the risks of adverse events; more studies are needed to Cellulitis-like reactions address this and several other priority safety issues with all influenza vaccines in children.
    [Show full text]
  • Recommended Adult Immunization Schedule
    Recommended Adult Immunization Schedule UNITED STATES for ages 19 years or older 2021 Recommended by the Advisory Committee on Immunization Practices How to use the adult immunization schedule (www.cdc.gov/vaccines/acip) and approved by the Centers for Disease Determine recommended Assess need for additional Review vaccine types, Control and Prevention (www.cdc.gov), American College of Physicians 1 vaccinations by age 2 recommended vaccinations 3 frequencies, and intervals (www.acponline.org), American Academy of Family Physicians (www.aafp. (Table 1) by medical condition and and considerations for org), American College of Obstetricians and Gynecologists (www.acog.org), other indications (Table 2) special situations (Notes) American College of Nurse-Midwives (www.midwife.org), and American Academy of Physician Assistants (www.aapa.org). Vaccines in the Adult Immunization Schedule* Report y Vaccines Abbreviations Trade names Suspected cases of reportable vaccine-preventable diseases or outbreaks to the local or state health department Haemophilus influenzae type b vaccine Hib ActHIB® y Clinically significant postvaccination reactions to the Vaccine Adverse Event Hiberix® Reporting System at www.vaers.hhs.gov or 800-822-7967 PedvaxHIB® Hepatitis A vaccine HepA Havrix® Injury claims Vaqta® All vaccines included in the adult immunization schedule except pneumococcal 23-valent polysaccharide (PPSV23) and zoster (RZV) vaccines are covered by the Hepatitis A and hepatitis B vaccine HepA-HepB Twinrix® Vaccine Injury Compensation Program. Information on how to file a vaccine injury Hepatitis B vaccine HepB Engerix-B® claim is available at www.hrsa.gov/vaccinecompensation. Recombivax HB® Heplisav-B® Questions or comments Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Human papillomavirus vaccine HPV Gardasil 9® Spanish, 8 a.m.–8 p.m.
    [Show full text]
  • Varicella (Chickenpox): Questions and Answers Q&A Information About the Disease and Vaccines
    Varicella (Chickenpox): Questions and Answers Q&A information about the disease and vaccines What causes chickenpox? more common in infants, adults, and people with Chickenpox is caused by a virus, the varicella-zoster weakened immune systems. virus. How do I know if my child has chickenpox? How does chickenpox spread? Usually chickenpox can be diagnosed by disease his- Chickenpox spreads from person to person by direct tory and appearance alone. Adults who need to contact or through the air by coughing or sneezing. know if they’ve had chickenpox in the past can have It is highly contagious. It can also be spread through this determined by a laboratory test. Chickenpox is direct contact with the fluid from a blister of a per- much less common now than it was before a vaccine son infected with chickenpox, or from direct contact became available, so parents, doctors, and nurses with a sore from a person with shingles. are less familiar with it. It may be necessary to perform laboratory testing for children to confirm chickenpox. How long does it take to show signs of chickenpox after being exposed? How long is a person with chickenpox contagious? It takes from 10 to 21 days to develop symptoms after Patients with chickenpox are contagious for 1–2 days being exposed to a person infected with chickenpox. before the rash appears and continue to be conta- The usual time period is 14–16 days. gious through the first 4–5 days or until all the blisters are crusted over. What are the symptoms of chickenpox? Is there a treatment for chickenpox? The most common symptoms of chickenpox are rash, fever, coughing, fussiness, headache, and loss of appe- Most cases of chickenpox in otherwise healthy children tite.
    [Show full text]
  • 2021 Medicare Vaccine Coverage Part B Vs Part D
    CDPHP® Medicare Advantage Vaccine Coverage Guide Part B (Medical) vs. Part D (Pharmacy) Medicare Part B (Medical): Medicare Part D (Pharmacy): Vaccinations or inoculations Vaccinations or inoculations are included when the administration is (except influenza, pneumococcal, reasonable and necessary for the prevention of illness. and hepatitis B for members at risk) are excluded unless they are directly related to the treatment of an injury or direct exposure to a disease or condition. • Influenza Vaccine (Flu) • BCG Vaccine • Pneumococcal Vaccine • Diphtheria/Tetanus/Acellular Pertussis Vaccine (ADACEL, (Pneumovax, Prevnar 13) BOOSTRIX, DAPTACEL, INFANRIX) • Hepatitis B Vaccine • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus (Recombivax, Engerix-B) Vaccine (KINRIX, QUADRACEL) for members at moderate • Diphtheria/Tetanus Vaccine (DT, Td, TDVAX, TENIVAC) to high risk • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus Vac­ • Other vaccines when directly cine/ Haemophilus Influenzae Type B Conjugate Vaccine (PENTACEL) related to the treatment of an • Diphtheria/Tetanus/Acellular Pertussis/Inactivated Poliovirus injury or direct exposure to a Vaccine/Hepatitis B Vaccine (PEDIARIX) disease or condition, such as: • Haemophilus Influenzae Type B Conjugate Vaccine (ActHIB, PedvaxHIB, • Antivenom Sera Hiberix) • Diphtheria/Tetanus Vaccine • Hepatitis A Vaccine, Inactivated (VAQTA) (DT, Td, TDVAX, TENIVAC) • Hepatitis B Vaccine, Recombinant (ENGERIX-B, RECOMBIVAX HB) • Rabies Virus Vaccine for members at low risk (RabAvert,
    [Show full text]
  • Varicella/Chickenpox (VAR)
    Vaccine Fact Sheet Varicella/Chickenpox (VAR) Brand Name and Manufacturer Varivax® Merck Protects Against Varicella Zoster Virus (chickenpox) Routine Schedule Two (2) dose series: First dose at 12-15 months and second dose at 4-6 years Minimum Intervals Younger than 13 years of age: 3 month minimum interval between doses 13 years of age and older: 4 week minimum interval between doses Approved for use in Persons aged 12 months and older Administration Subcutaneous (SC) injection Packaging Vaccine is packaged as 10 single-dose vials of lyophilized vaccine and a separate box of 10 single-dose 0.7mL vials of sterile diluent Storage Freeze between -58ºF and +5ºF (-50ºC to -15ºC) STORE IN FREEZER PROTECT VACCINE FROM LIGHT Full ACIP Recommendations https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/varicella.html VFC Letter Not available on EZIZ Billing Codes CHDP code: 46 CPT code for vaccine: 90716 CPT code for administration: 90460 Medi-Cal Fee-For-Service (FFS) administration: 90716 with modifiers –SK (high-risk) and –SL (VFC) ICD-10-CM code (encounter for immunization): Z23 *http://www.aafp.org/practice-management/payment/coding/admin.html Comments • Licensed in 1995 • Use only the Merck sterile diluent to reconstitute lyophilized varicella vaccine • Varicella vaccine must be used within 30 minutes of reconstitution • Store sterile diluent separately at room temperature (68ºF to 77ºF) or in the refrigerator • If varicella, MMR, and/or LAIV are not administered at the same visit, they should be separated by at least 28 days. • Persons who are immunocompromised due to certain conditions or treatments or who are pregnant should not be vaccinated with varicella vaccine California Department of Public Health, Immunization Branch IMM-1078 VFCvaccinefactsheet_Varicella (4-17) EZIZ.ORG.
    [Show full text]
  • Vaccinations for Pregnant Women the Table Below Shows Which Vaccinations You May Or May Not Need During Your Pregnancy
    Vaccinations for Pregnant Women The table below shows which vaccinations you may or may not need during your pregnancy. Vaccine Do you need it during your pregnancy? Influenza Yes! You need a flu shot every fall (or even as late as winter or spring) for your protection and for the protection of your baby and others around you. It’s safe to get the vaccine at any time during your pregnancy. Tetanus, diphtheria, Yes! Women who are pregnant need a dose of Tdap vaccine (the adult whooping cough vaccine) during each pregnancy, prefer- whooping cough ably in the early part of the third trimester. It’s safe to be given during pregnancy and will help protect your baby from whooping (pertussis) cough in the first few months after birth when he or she is most vulnerable. After Tdap, you need a Tdap or Td booster dose every Tdap, Td 10 years. Consult your healthcare provider if you haven’t had at least 3 tetanus- and diphtheria-toxoid containing shots some- time in your life or if you have a deep or dirty wound. Human No. This vaccine is not recommended to be given during pregnancy, but if you inadvertently receive it, this is not a cause for papillomavirus concern. HPV vaccine is recommended for all people age 26 or younger, so if you are in this age group, make sure you are HPV vaccinated before or after your pregnancy. People age 27 through 45 may also be vaccinated against HPV after discussion with their healthcare provider. The vaccine is given in 2 or 3 doses (depending on the age at which the first dose is given) over a 6-month period.
    [Show full text]
  • Adult Immunizations
    Guidelines for Clinical Care Ambulatory Immunizations Guideline Team Adult Immunizations Team Leads Susan F Engert, MD, MPH Population: Adults, >18 years old Pediatrics and Communi- cable Diseases Objectives: Implement an evidence-based strategy for routine adult immunizations. Candia B Laughlin, RN, Key Points MS Routine immunizations for adults are: hepatitis A, hepatitis B, herpes zoster, human papilloma virus, Ambulatory Care Nursing Administration influenza, measles, mumps, rubella, meningococcal, pneumococcal, tetanus, diphtheria, pertussis and Team Members varicella. Below is a summary on priority populations, initial vaccination, and revaccination. Margie C Andreae, MD Use combination vaccines whenever possible to increase the coverage rates for vaccine-preventable Pediatrics and Communi- diseases: Tetanus-diphtheria (Td), Tetanus-diphtheria-acellular pertussis (Tdap), Measles-Mumps- cable Diseases Rubella (MMR), hepatitis A-hepatitis B (Twinrix®). Single antigen vaccines have no safety advantage. Mary K.Barry-Bodine, Live virus vaccines (Herpes Zoster, Measles-Mumps-Rubella, Varicella and Live Attenuated Influenza RN, BSN Vaccine) are contraindicated in persons who are pregnant or may become pregnant in the next four Nursing, Health Centers weeks, or who have immunocompromising conditions. If administering multiple live vaccines, give Susan G Blitz, MD, MPH simultaneously or separate them by 4 weeks. Tuberculosis (PPD) skin test should be administered General Medicine before or on the same day as a live virus vaccine or they need to be spaced 4-6 weeks apart. Katie Barwig, RN, MS This guideline follows recommendations of the federal Advisory Committee on Immunization Practices: Nursing Administration These vaccinations should be performed [strength of recommendation] for indicated populations at risk. Sherry L DeLoach, Evidence for each vaccine is based on randomized controlled trials [level of evidence] in general PharmD population and some subgroups, with findings extrapolated to some subgroups.
    [Show full text]
  • Global Advisory Committee on Vaccine Safety (GACVS)
    Global Advisory Committee on Vaccine Safety (GACVS) Report on GACVS meeting June 2013 1 | GACVS June 2013 report Topics Discussed ! Pentavalent vaccine in 4 Asian Countries ! Zoster vaccine safety and varicella vaccine safety in immunocompromised populations ! Immunization during pregnancy ! Yellow fever vaccine safety during mass immunization campaigns in sub-Saharan Africa ! Safety profile: Japanese encephalitis vaccines ! Update: human papillomavirus vaccines ! Update: pandemic influenza vaccine (Pandemrix®) and narcolepsy 2 | GACVS June 2013 report Progressive pentavalent vaccine introduction in 4 Asian Countries ! Sri Lanka (Crucell, Jan 2008): – Within 3 months, 4 deaths and 24 suspected HHE: precautionary suspension of initial lot. – 1 death following immunization April 2009: vaccine suspended, DTwP and Hep B resumed. ! Bhutan (Panacea, Sep 2009) – 5 cases of encephalopathy and/or meningoencephalitis lead to suspended vaccination 23 Oct 2009. (Subsequently, 4 serious AEFI were identified and investigated). ! India (Serum Institute of India, Tamil Nadu and Kerala, Dec 2011; Goa, Pondicherry, Karnataka, Haryana, Jammu and Kashmir, Gujarat and Delhi from Q3 2012 – Q1 2013) – To date, 83 AEFI cases reported, some associated with mortality. ! Vietnam (Crucell, Jun 2010 - May 2013) – 43 serious AEFI investigated, including 27 with fatal outcome. – Following 9 deaths following vaccination reported Dec 2012 - March 2013: vaccine suspended. 3 | GACVS June 2013 report GACVS analysis of common features among countries experiencing significant vaccine safety concerns ! Vaccination programmes are well established and achieves high coverage ! Vaccine introduction was accompanied by thorough training of health-care staff on benefits and risks of vaccine ! Sri Lanka and Bhutan: discontinuation and resumption of pentavalent vaccine did not significantly modify pattern of serious AEFI with previously utilized vaccines ! Limitations in all 4 countries: – Incomplete clinical information complicated causality assessment.
    [Show full text]
  • COVID-19 Vaccine Frequently Asked Questions for Healthcare Professionals
    COVID-19 Vaccine Frequently Asked Questions for Healthcare Professionals Table of Contents Vaccine Development and Approval 7 1) Is there a vaccine that protects against COVID-19 (SARS-CoV-2)? 7 2) When can we expect a vaccine to be available? 7 3) Why is this COVID-19 vaccine development timeline so condensed compared to when other vaccines are licensed? 7 4) The development and production of a COVID-19 vaccine has been called “Operation Warp Speed”, does this mean shortcuts have been taken? 8 5) What types of COVID-19 vaccines are in clinical trials? 9 6) How does the size of COVID-19 vaccine clinical trials compare to clinical trials for other vaccines routinely used in the United States? 10 7) Are people from different races and ethnicities being included in clinical trials for COVID- 19 vaccines? 10 8) What will be needed to license a COVID-19 vaccine in the United States? 10 9) What is Emergency Use Authorization? 11 10) Can you explain the difference between EUA and a Biological License Application (BLA)? 11 11) Why might the FDA issue an EUA before a BLA for a COVID-19 vaccine? 11 COVID-19 Vaccine Safety and Efficacy 12 12) Is the COVID-19 vaccine safety tested? 12 13) What is the current safety and efficacy of COVID-19 vaccines in clinical trials? 12 14) What is efficacy? Is there a difference between vaccine efficacy and effectiveness? 12 15) How does the efficacy of the Pfizer and Moderna vaccines compare to other vaccines? 13 16) What is the efficacy of the COVID-19 vaccine if I only receive one dose? 13 17) Is it true that people in the COVID-19 vaccine clinical trials died? 13 18) How will safety of the COVID-19 vaccine be monitored? 13 19) Is the COVID-19 vaccine being studied in children or pregnant women? 14 20) If vaccine trials do not include people with autoimmune conditions, how will we know if they can be vaccinated? 14 1 21) Do COVID-19 vaccines cause people to faint? 14 22) Can individuals with an allergy to latex receive a COVID-19 vaccine? 14 23) I heard reports of anaphylaxis following receipt of the Pfizer COVID-19 vaccine.
    [Show full text]